Abstract
Introduction
Antibiotics remain one of the most significant health achievements to date. However, antimicrobial resistance is regarded as one of the greatest threats to human health. Studies have found resistance genes in 30,000-year-old frozen bacterial DNA in the Arctic and 4-million-year-old bacterial samples recovered from underground caves which were isolated from human exposure. 1, 2 Enhancing this evolutionary process is antibiotic exposure. 2 The widespread use of antimicrobials among humans and animals along with a globalized society and travel leads to spread of resistant strains worldwide. 3 More than one-third of community-associated infections caused by extended spectrum beta lactamase (ESBL) producing Escherichia coli occurred in patients without healthcare-associated risk factors. 4 There is a significant association between recent antibiotic use and the presence of ESBL-producing Enterobacteriaceae among community patients newly admitted to the hospital. 5 A 10-year study showed that the nationwide prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa has remained high and has increased in pneumonia and blood stream infections. 6 The prevalence of MDR Gram-negative bacteria varies, but incidence is steadily rising. 6, 7 E. coli resistance to fluoroquinolones increased from 3% in 1999 to >20% in 2010. 7 There is a rising prevalence of MDR P. aeruginosa and carbapenem-resistant Enterobacteriaceae (CRE) in the United States. 6, 8 Patients with MDR Gram-negative bacterial infections are more likely to receive ineffective initial therapy and face worse outcomes, such as increased mortality and longer hospital stays. 9 The Centers for Disease Control and Prevention (CDC) reported 57% increase in mortality in blood stream infection caused by ESBL-producing organisms as compared to non-ESBL-producing organisms. 7 Gram-negative bacteria have a variety of mechanisms to develop resistance to current antibiotics and are capable of rapidly transferring these mechanisms to other bacteria via plasmids. 10 Over the course of the past several years, the antimicrobial resistance pattern among the Gram-negative bacteria has rapidly changed, while the development of effective antibiotics has been limited. With the emergence of ESBLs, choices of antibiotics were narrowed to carbapenems. Recently, with the emergence of New Delhi metallo beta lactamase (NDM-1) and Klebsiella pneumoniae Carbapenemase (KPC), even carbapenems are not effective. 11, 12 Quantification of the prevalence and identification of risk factors for MDR GNB have important implications for patient care. 13 Very few studies have been published to identify the risk factors for multidrug Gram-negative bacilli (GNB) bacteremia. Most of these studies have focused on either critically ill patients, pediatric patients, or neutropenic patients. Our study is the first study to focus general hospital patients as well as included critically ill and neutropenic cancer patients. Purpose of this study was to identify the risk factors for the MDR GNB as well as to define risk factors associated with mortality in patients with GNB.
Methods
This study was a retrospective observational cohort study conducted at the Saint Louis University Hospital in Missouri, USA. Study duration was from 1 July 2013 to 31 July 2014. Study objectives were to identify the incidence, risk factors, and outcome of multidrug-resistant GNB bacteremia. All patients aged 18 years and older with at least one episode of GNB bacteremia during a hospital admission were included in the study. There were no other exclusion criteria. If a patient had multiple admissions for GNB, they were included in the study as different episodes. However, if a patient developed recurrence of bacteremia during the same admission, it was considered as a singlepatient episode. Patients were identified by electronic search for positive blood culture demonstrating GNB in the hospital's microbiology datasets. At the time of study, our hospital was not using rapid diagnostic test to identify the organism. The study was approved by the Institutional Review Board of Saint Louis University Hospital.
Patients' electronic health records were reviewed. Data collection included the following clinical variables: (a) age, gender, and race; (b) co-morbid conditions; (c) abdominal/thoracic surgery in last 4 weeks; (d) use of antibiotics in last 30 days; (e) source of infection; (f) length of hospitalization ⩾72 h before the onset of GNB; (g) use of a central venous catheter ⩾48 h before the onset of GNB; (h) use of mechanical ventilation for ⩾72 h before the onset of GNB; (i) use of total parenteral nutrition (TPN) ⩾72 h before GNB; (j) antimicrobial resistance patterns in GNB blood culture isolates; (k) antibiotics used to treat the infection (empiric and targeted); (l) appropriateness of empiric antibiotics as well as source control; (m) time to negative blood culture; and (n) mortality within 30 days.
Study definitions
1. Criteria from the CDC for MDR organism were applied and MDR Gram-negative bacteria were defined as (a) ESBLproducing Enterobacteriaceae; (b) microorganisms with intrinsic resistance mechanisms such as Stenotrophomonas maltophilia, Burkholderia cepacia, and Ralstonia pickettii; and (c) any GNB (e.g. Acinetobacter spp., Enterobacteriaceae, and Pseudomonas spp.) resistant to three or more of the following drug class: piperacillin/tazobactam, cephalosporins (cefazolin, ceftriaxone, ceftazidime, and cefepime), carbapenems (imipenem), monobactams (aztreonam), aminoglycosides (gentamicin, tobramycin, and amikacin), and fluoroquinolones (ciprofloxacin and levofloxacin). 14 
Previous antibiotic therapy was defined as
systemic antibiotic use for at least 72 h in the preceding 30 days before onset of bacteremia. 3. Inappropriate empiric antibiotic therapy was defined as treatment regimen that did not include at least one antibiotic that was active in vitro against the infecting microorganisms within 24 h of blood culture collection. 4. Recurrence of bacteremia was defined as the emergence of a positive blood culture with same GNB after ⩾1 negative blood culture and after an interval of ⩾7 days. 5. All-cause mortality was defined as death by any cause within 30 days of the onset of bacteremia. (Table 6 ).
Statistical analysis

Discussion
The prevalence of MDR among GNB is rapidly increasing. Quantification of the prevalence and the common antimicrobial resistance patterns of MDR GNB isolates recovered from patients at hospital admission, as well as identification of patients with a high risk of harboring MDR GNB, would have important implications for patient care. 13 Our study found that 26% of GNB at the institution are MDR and case fatality rate was 34%. Gudiol et al. studied 372 episodes of GNB in neutropenic patient. Of those episodes, 13.7% were caused by MDR GNB with a case fatality rate of 41% as compared to 21% with non-MDR GNB. 15 Tsai studied 393 episodes of GNB in a pediatric population. Incidence of MDR GNB was 18.6% with a case fatality rate of 21.4% as compared to 10.5% in the non-MDR population. 16 Blot et al. 17 studied 328 patients with GNB in an intensive care unit (ICU) setting during a 9-year period; 36% of episodes were related to MDR, with a case fatality rate of 45%. Our study differs from these studies in that our patients were heterogeneous group: malignant as well as nonmalignant patients and general floor as well ICU patients; this could have accounted for lower overall mortality in our study population.
Our study provided important risk factors for the development of MDR GNB and predictors for mortality. DM, urinary catheter as a source of infection, and previous antibiotic use predicted the development of MDR GNB similar to prior studies.
Michalopoulas et al. 18 studied 50 episodes of GNB in the ICU. DM was the only significant risk factor for the development of MDR GN bacteremia. Gudiol et al. 15 found that male sex, previous antibiotic therapy, and urinary catheter as a source of infection were significant risk factors for the development of MDR GNB in patients with cancer and neutropenia.
Significant risk factors for morality in our study included the following: (a) end-stage liver disease, (b) solid organ malignancy, (c) intraabdominal source of infection, (d) urinary catheter as a source of infection, and (e) inappropriate empiric antibiotic therapy. Our study is unique as our hospital is a major liver transplant and cancer center.
Lye studied 675 patients with GNB bacteremia; 301 had MDR GNB bacteremia. Risk factors for 
Burkholderia cepacia 1 (2.2) 0
Enterobacter species (cloacae complex/aerogenes/ gergoviae)
(2.2) 12 (9.2)
Achromobacter species (Achromobacter denitrificans/Achromobacter xylosoxidans) higher mortality included the following: male gender, higher APACHE II score, higher Charlson comorbidity index, ICU stay, and the presence of concomitant pneumonia. 19 A metaanalysis of 32 studies performed by Rottier concluded that ESBL was associated with higher mortality, but after adjustment for inadequate empiric antibiotics, it was found that inadequate empiric antibiotic was responsible for most of the mortality attributed to the ESBL-producing organisms. 20 Blot reported that age, 'high-risk' bacteremia (intra-abdominal and lower respiratory tract source of infection leading to bacteremia), higher APACHE II score, acute renal failure, and Pseudomonas spp. bacteremia were risk factors for mortality. 17 Gudiol et al. 15 found that solid tumor, current steroid therapy, ICU admission, and MDR GNB were significant risk factors for mortality in cancer patients.
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Limitations for our study include the following: (a) single-center study, (b) retrospective analysis of clinical data, (c) relatively smaller sample size, (d) small number of patients with pneumonia which is considered a risk factor for mortality and MDR bacteremia in other studies, and (e) time to source control was not addressed in this study, which can impact the mortality rate.
In summary, the incidence of MDR GNB is increasing and associated with high mortality. Independent risk factors like DM, presence of urinary catheters, and receipt previous antibiotics were predictors for the development of MDR GNB bacteremia. Risk factors like end-stage liver disease, solid organ malignancy, intra-abdominal infection, urinary catheter as a source of infection, and inappropriate empiric antibiotics therapy were associated with higher mortality. MDR bacteremia was not associated with the recurrence. Further studies are needed to define the optimal strategy for the empirical treatment of patients at the risk for MDR GNB bacteremia.
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